share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K:重大事件
美股SEC公告 ·  07/15 08:04

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has reported the issuance of 1,975,283 shares of common stock on July 11, 2024. This issuance was a result of investors exercising warrants previously issued by the company. The company received proceeds of approximately $2.67 million from this exercise. Following the issuance, the total number of outstanding shares of Virpax Pharmaceuticals' common stock increased to 4,813,181. The shares were issued under a registration statement on Form S-1, which was declared effective on May 14, 2024. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol VRPX. The report was officially signed by Gerald Bruce, the Chief Executive Officer of Virpax Pharmaceuticals, on July 15, 2024.
Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has reported the issuance of 1,975,283 shares of common stock on July 11, 2024. This issuance was a result of investors exercising warrants previously issued by the company. The company received proceeds of approximately $2.67 million from this exercise. Following the issuance, the total number of outstanding shares of Virpax Pharmaceuticals' common stock increased to 4,813,181. The shares were issued under a registration statement on Form S-1, which was declared effective on May 14, 2024. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol VRPX. The report was officially signed by Gerald Bruce, the Chief Executive Officer of Virpax Pharmaceuticals, on July 15, 2024.
Virpax药品公司是一家总部位于特拉华州的新兴成长公司,于2024年7月11日申报发行了1975283股普通股。此次发行是由公司之前发行的权证持有人所行使的。该公司此次行使权证获得了大约$267万美元的收益。在此次发行后,Virpax药品公司的普通股总股数增加至4813181股。这些股票是根据在2024年5月14日生效的S-1表格的注册声明发行的。该公司的普通股在纳斯达克交易市场上以VRPX股票交易。此报告由Virpax药品公司的首席执行官Gerald Bruce于2024年7月15日正式签署。
Virpax药品公司是一家总部位于特拉华州的新兴成长公司,于2024年7月11日申报发行了1975283股普通股。此次发行是由公司之前发行的权证持有人所行使的。该公司此次行使权证获得了大约$267万美元的收益。在此次发行后,Virpax药品公司的普通股总股数增加至4813181股。这些股票是根据在2024年5月14日生效的S-1表格的注册声明发行的。该公司的普通股在纳斯达克交易市场上以VRPX股票交易。此报告由Virpax药品公司的首席执行官Gerald Bruce于2024年7月15日正式签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息